28-08-2020
Sundry Photography / Shutterstock.com
Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Genentech, Hemlibra, patent, Takeda, infringement, haemophilia, Federal Circuit, claim construction, Baxalta
Genentech prevails in Baxalta haemophilia treatment suit
17-01-2022
Taiwanese biotech built on ‘foundation of lies’, says DoJ
08-07-2021
Fed Circuit affirms cancellation of Anacor antifungal patents
01-09-2020
Former Genentech employee cuts plea deal with FBI in trade secrets case
16-01-2020
UK court overturns Genentech patent, cites Brexit in CJEU referral
01-03-2019
